You are here: Industry Insights > AbCellera

News List

AbCellera provides Covid-19 programme update with start of phase 3 clinical trials pharmaceutical-business-review
August 05, 2020
AbCellera announced that LY-CoV555, a human antibody discovered by AbCellera in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC) and co-developed with Eli Lilly and Company (Lilly) as ...
Lilly, AbCellera Dose First Patients with COVID-19 Antibody contractpharma
June 02, 2020
Phase 1 study of LY-CoV555 is the world's first study of a potential antibody treatment designed to fight COVID-19.
AbCellera raises $105m for antibody drug discovery platform pharmaceutical-technology
May 28, 2020
Canadian biotech firm AbCellera Biologics has raised $105m in a Series B funding round to advance its artificial intelligence (AI)-powered antibody drug discovery platform.
Canada provides $175.6m for AbCellera to develop Covid-19 therapies pharmaceutical-technology
May 05, 2020
The Canadian government has agreed to provide up to $175.6m to support AbCellera in the development of antibody-based therapies against Covid-19.
AbCellera, Lilly Partner to Develop Antibodies Against COVID-19 contractpharma
March 16, 2020
Will leverage AbCellera's rapid pandemic response platform and Lilly's global development, manufacturing and distribution capabilities.
Gilead, AbCellera team up against infectious diseases pharmatimes
June 16, 2019
AbCellera has announced a partnership with Gilead to discover antibodies for infectious disease.
AbCellera and Novartis enter into multi-target partnership pharmaceutical-technology
February 15, 2019
Canada-based AbCellera has announced it has signed a multi-year, multi-target agreement with Novartis under which its antibody discovery technology will be leveraged by the Swiss pharma giant for up to ten clinically-relevant disease targets....
AbCellera Collaborates with Autolus on Antibody Discovery Project pharmafocusasia
November 30, 2018
AbCellera announced today its collaboration with Autolus Therapeutics plc (Autolus), a clinical stage biopharmaceutical company developing next-generation programmed T cell therapies.....

Previous page 1 2 Next page